Inpharma Weekly

, Volume 1025, Issue 1, pp 9–10 | Cite as

Prodrugs utilised to improve tumour targeting

  • Gill Higgins
Newsletter Article


By targeting tumour cells more accurately, it may be possible to significantly improve the efficacy of antineoplastic therapy, say cancer specialists. The use of nontoxic prodrugs is being hailed as a possible way of achieving this goal. Progress is being made with both antibody-and gene-directed enzyme/prodrug therapy (ADEPT and GDEPT, respectively) in oncology laboratories around the world. Some of the latest developments were reported at the 25th Jubilee Conference of the New Zealand Society for Oncology [ Auckland, New Zealand; February 1996 ].


Zealand Society Enzyme Prodrug Therapy Human Colorectal Carcinoma Cell Line NADH Cofactor Nitroreductase Activation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1996

Authors and Affiliations

  • Gill Higgins

There are no affiliations available

Personalised recommendations